Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.

The Fosun-backed smart apparel technology provider has filed to raise just over $50m on the Shenzhen Stock Exchange’s ChiNext market.

The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.

The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.

Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.

New World Development and China Mobile Games and Entertainment will have the chance to exit the Asia-based gay dating app developer.

Chalmers Ventures portfolio company Biofrigas has set out plans for a $1.7m IPO but has already issued around $1.2m to existing connections.

Novartis and Eli Lilly are set to score exits from the cancer and blood disease drug developer in an initial public offering set to raise up to $212m.

The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.